multiple sclerosis

The European Journal of Neurology continues to attract a considerable number of original submissions, and can only publish approximately 15% of those received. Articles cover a broad range of clinical and scientific topics within neurology, but the proportion of articles on a disease area generally corresponds to its prevalence.

By Brigit de Jong Multiple sclerosis (MS) research has a longstanding history in the Netherlands with an impressive impact on global knowledge related to MS pathogenesis, diagnosis and treatment. During the time period where no disease modifying treatments options were… Continue Reading

For November 2016 we have selected: Cree BAC, Gourraud P-A, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016:80;499-510. Studies describing the natural history of multiple sclerosis (MS) before the availability of disease-modifying treatments have reported a progression of the disease from the relapsing-remitting form to the secondary progressive form in about 50% of patients at 19 years after the onset.

By Jose E. Martínez-Rodríguez
More than 9000 participants attended the 32nd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 21st Annual Conference of Rehabilitation in MS in London from September 14th to17th.… Continue Reading

By Trevor Owens Basic MS Research can be defined as analysis of mechanism of induction, pathogenesis and regulation of neuroinflammatory demyelinating disease using in vivo and in vitro experimental models. This is an area of longstanding and growing strength for… Continue Reading

or April 2016 we have selected: Lublin F, Miller DH, Freedman MS, et al., on behalf of the INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Neurol, 27 Jan 2016; pii: S0140-6736(15)01314-8. doi: 10.1016/S0140-6736(15)01314-8. Primary progressive multiple sclerosis (PPMS) represents around 10-15% of the clinical forms of MS. Several characteristics differentiate PPMS from the relapse-onset MS, the classical more frequent form: older age at onset, equal prevalence between sexes, less inflammatory component at the MRI, and quicker progression of disability.